FIRMAGON Powder and solvent for solution for injection (2020)
Βιβλιογραφική αναφορά
Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Περιεχόμενα
Name of the medicinal product
FIRMAGON 80 mg powder and solvent for solution for injection.
Qualitative and quantitative composition
Each vial contains 80 mg degarelix (as acetate). After reconstitution, each ml of solution contains 20 mg of degarelix. For the full list of excipients, see section 6.1.
Pharmaceutical form
Powder and solvent for solution for injection. <u>Powder:</u> White to off-white powder. <u>Solvent:</u> Clear, colourless solution.
Therapeutic indications
FIRMAGON is a gonadotrophin releasing hormone (GnRH) antagonist indicated for treatment of adult male patients with advanced hormone-dependent prostate cancer.
Posology and method of administration
Posology <u>Starting dose:</u> 240 mg administered as two consecutive subcutaneous injections of 120 mg each. <u>Maintenance dose – monthly administration:</u> 80 mg administered as one subcutaneous injection. ...
Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.
Special warnings and precautions for use
Effect on QT/QTc interval Long-term androgen deprivation therapy may prolong the QT interval. In the confirmatory study comparing FIRMAGON to leuprorelin periodic (monthly) electrocardiograms (ECGs) were ...
Interaction with other medicinal products and other forms of interaction
No formal drug-drug interaction studies have been performed. Since androgen deprivation treatment may prolong the QTc interval, the concomitant use of degarelix with medicinal products known to prolong ...
Fertility, pregnancy and lactation
Pregnancy and breast-feeding There is no relevant indication for use of FIRMAGON in women. Fertility FIRMAGON may inhibit male fertility as long as the testosterone is suppressed.
Effects on ability to drive and use machines
FIRMAGON has no or negligible influence on the ability to drive and use machines. Fatigue and dizziness are common adverse reactions that might influence the ability to drive and use machines.
Undesirable effects
Summary of the safety profile The most commonly observed adverse reactions during degarelix therapy in the confirmatory phase III study (N=409) were due to the expected physiological effects of testosterone ...
Overdose
There is no clinical experience with the effects of an acute overdose with degarelix. In the event of an overdose the patient should be monitored and appropriate supportive treatment should be given, if ...
Pharmacodynamic properties
Pharmacotherapeutic group: Endocrine therapy, Other hormone antagonists and related agents ATC code: L02BX02 Mechanism of action Degarelix is a selective gonadotrophin releasing-hormone (GnRH) antagonist ...
Pharmacokinetic properties
Absorption Following subcutaneous administration of 240 mg degarelix at a concentration of 40 mg/ml to prostate cancer patients in the pivotal study CS21, AUC<sub>0-28days</sub> was 635 (602-668) day*ng/ml, ...
Preclinical safety data
Animal reproduction studies showed that degarelix caused infertility in male animals. This is due to the pharmacological effect; and the effect was reversible. In female reproduction toxicity studies degarelix ...
List of excipients
Powder: Mannitol (E421) Solvent: Water for injections
Incompatibilities
In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.
Shelf life
3 years. After reconstitution: Chemical and physical in-use stability has been demonstrated for 2 hours at 25oC. From a microbiological point of view, unless the method of reconstitution precludes the ...
Special precautions for storage
This medicinal product does not require any special storage conditions. For storage conditions of the reconstituted medicinal product, see section 6.3.
Nature and contents of container
Glass (type I) vial with bromobutyl rubber stopper and aluminium flip-off seal containing 80 mg powder for solution for injection. Pre-filled glass (type I) syringe with elastomer plunger stopper, tip ...
Special precautions for disposal and other handling
The instructions for reconstitution must be followed carefully. Administration of other concentrations is not recommended because the gel depot formation is influenced by the concentration. The reconstituted ...
Marketing authorization holder
Ferring Pharmaceuticals A/S, Kay Fiskers Plads 11, DK-2300, Copenhagen S, Denmark, Tel: +45 88 33 88 34
Marketing authorization number(s)
EU/1/08/504/001 EU/1/08/504/003
Date of first authorization / renewal of the authorization
Date of first authorisation: 17/02/2009 Date of latest renewal: 19/09/2013
Πηγαίο έγγραφο
Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση:
